The team at the Westmead Institute is involved in clinical trials in the Westmead Hospital and pre-clinical laboratory work in the Westmead Institute including:

  • A Phase I Study of CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Persistent and Relapsed B-cell Leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study).
  • Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination to Enhance Infection-Specific Immune Reconstitution Post-Allogeneic Stem Cell Transplantation (CYNTAX).
  • A clinical trial of donor-derived WT1 specific T cells for prevention of relapse in combination with multiple pathogen specific T cells for prevention of infection in patients undergoing allogeneic haemopoietic stem cell transplant (INTACT-WT1).
  • Therapeutic infusion of most closely HLA-matched third party donor-derived virus- and fungus specific cytotoxic T-lymphocytes in patients with active viral reactivation or proven or probable invasive fungal infection post-allogeneic stem cell or solid organ transplantation (R3ACT).
  • Chemotherapy followed by infusion of partially HLA matched unrelated donor cells for patients with AML who are ineligible for stem cell transplantation (SCRAMBLE).
  • Phase I Study of the Administration of “Off The Shelf” Virus-Specific T-cells Expressing a non-MHC restricted CD19 Specific Chimeric Antigen Receptor For Therapy of Relapsed and Refractory B-Cell Malignancies (UNI-T Study).
  • Preclinical studies of gene modified T cells expressing a chimeric antigen receptor to treat multiple myeloma.
  • Preclinical studies of expanded NK cells for treatment of malignancies.
  • Analysis of gene expression in acute leukaemias.
  • Pre-clinical Optimization of Adoptive Cellular therapy for HPV-associated high-grade lesions and malignancies. (POACH Study).